Conjugation of lymphoma idiotype to CD40 antibody enhances lymphoma vaccine immunogenicity and antitumor effects in mice

Blood

Volumn 119, Issue 9, 2012, Pages 2056-2065

  Carlring, Jennifer ^a   Szabo, Marika J ^a   Dickinson, Robert ^a   De Leenheer, Evy ^a   Heath, Andrew W ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADX 40; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; KEYHOLE LIMPET HEMOCYANIN; LYMPHOMA VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG EFFICACY; EFFECTOR CELL; FEMALE; FOLLICULAR LYMPHOMA; HUMORAL IMMUNITY; IMMUNOGENICITY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 84857740444     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-05-355461     Document Type: Article

References (46)

1. Bendandi M. Aiming at a curative strategy for follicular lymphoma. CA Cancer J Clin. 2008;58(5): 305-317.
2. Stevenson GK, Stevenson FK. Antibody to a molecularly-defined antigen confined to a tumor cell surface. Nature. 1975;254(5502):714-716.
3. Baskar S, Kobrin CB, Kwak LW. Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes. J Clin Invest. 2004;113(10):1498-1510. (Pubitemid 39071706)
4. Navarrete MA, Heining-Mikesch K, Schüler F, et al. Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma. Blood. 2011;117(5):1483-1491.
5. George AJT, Tutt AL, Stevenson FK. Anti-idiotypic mechanisms involved in the suppression of a mouse B cell lymphoma, BCL1. J Immunol. 1987; 138(2):628-634. (Pubitemid 17002231)
6. Kaminski MS, Kitamura K, Maloney DG, Levy R. Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J Immunol. 1987;138(4):1289-1296. (Pubitemid 17017921)
7. Kwak LW, Young HA, Pennington RW, Weeks SD. Vaccination with synergistic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci U S A. 1996;93(20):10972- 10977.
8. Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long term results of a clinical trial. Blood. 1997;89(9):3129-3135.
9. Bendandi M, Gocke CD, Kobrin CB, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med. 1999;5(10):1171-1177. (Pubitemid 29474422)
10. Hurvitz SA, Timmerman JM. Current status of therapeutic vaccines for non-Hodgkin's lymphoma. Curr Opin Oncol. 2005;17(5):432-440. (Pubitemid 41224922)
11. Vose JM. Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach. Hematol Oncol. 2006;24(2):47-55. (Pubitemid 44023092)
12. Schuster SJ, Neelapu SS, Gause BL et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol. 2011;29(20): 2787-2794.
13. Ai WZ, Tibshirani R, Taidi B, Czerwinski D, Levy R. Anti-idiotype antibody response after vaccination correlates with overall survival in follicular lymphoma. Blood. 2009;113(23):5743-5746.
14. Pammer J, Plettenberg A, Weninger W, et al. CD40 antigen is expressed by endothelial cells and tumor cells in Kaposi's sarcoma. Am J Pathol. 1996;148(4):1387-1396. (Pubitemid 26135883)
15. Gallagher N, Eliopolous A, Kerr D, Young L. CD40 is expressed on epithelial ovarian cancer cells and modulates growth. Proc Am Assoc Cancer Res. 1997;38:500.
16. Kawaguchi Y, Saji S, Takita H, et al. Ligation of CD40 on the surface of human lung tumors suppresses tumor growth and enhances MHC class I expression. Proc Am Assoc Cancer Res. 1997; 38:346.
17. Kluth B, Hess S, Engelmann H, Schafnitzel S, Reithmuller G, Feucht H. Endothelial expression of CD40 in renal cell carcinoma. Cancer Res. 1997;57(5):891-899. (Pubitemid 27098014)
18. Posner MR, Cavacini LA, Upton MP, Gornstein ER, Norris Jr CM. Surface membrane-expressed CD40 is present on tumor cells from squamous cell cancer of the head and neck in vitro and in vivo and regulates cell growth in tumor cell lines. Clin Cancer Res. 1999;5(8):2261-2270. (Pubitemid 29399286)
19. Gordon J, Pound JD. Fortifying B cells with CD154, an engaging tale of many hues. Immunology. 2000;100(3):269-280. (Pubitemid 30449940)
20. van Kooten C, Banchereau J. Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol. 1997;9(3):330-337. (Pubitemid 27303501)
21. Ridge JP, DiRosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T helper and a T killer cell. Nature. 1998; 393(6684):474-478.
22. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic T-cell responses is mediated by CD40 signalling. Nature. 1998;393(6684):478-480.
23. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393(6684):480-483.
24. Barr TA, McCormick AL, Carlring J, Heath AW. A potent adjuvant effect of CD40 antibody attached to antigen. Immunology. 2003;109(1):87-91.
25. Carlring J, Barr TA, McCormick AL, Heath AW. CD40 antibody as an adjuvant induces enhanced T cell responses. Vaccine. 2004;22(25-26):3323-3328. (Pubitemid 39078748)
26. Cluff CW. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv Exp Med Biol. 2010;667(1):111-123.
27. Myers KR, TruchotAT,Ward J, Hudson Y, Ulrich JT. Acritical determinant of lipidAendotoxic activity. In: Nowotny A, Spitzer JJ, Ziegler EJ, eds. Cellular and Molecular Aspects of Endotoxin Reactions. Amsterdam, The Netherlands: Elsevier; 1990:145-156.
28. Ulrich JT, Masihi KN, Lange W. Mechanisms of nonspecific resistance to microbial infections induced by trehalose dimycolate (TDM) and monophosphoryl lipid A (MPL). In: Masihi KN, Lange W, eds. Advances in the Biosciences. London, United Kingdom: Pergamon Journals; 1988:167- 178.
29. Barr TA, Carlring J, Heath AW. CD40 antibody as a potent immunological adjuvant: CD40 antibody provides the CD40 signal to B cells, but does not substitute for T cell help in responses to TD antigens. Vaccine. 2005;23(26):3477-3482. (Pubitemid 40517123)
30. Betting DJ, Kafi K, Abdollahi-Fard A, Huvitz SA, Timmermann JM. Sulphydryl-based tumor antigen-based protein conjugates stimulate superior antitumor immunity against B cell lymphomas. J Immunol. 2008;181(6):4131-4140.
31. Randall TD, Heath AW, Santos-Argumedo L, Howard MC, Weissmanm IL, Lund FE. Arrest of B lymphocyte terminal differentiation by CD40 signaling: mechanism for lack of antibody-secreting cells in germinal centers. Immunity. 1998;8(6):733-742. (Pubitemid 28294520)
32. Workman P, Aboagye EO, Balkwill F, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010;102(11):1555-1577.
33. Grcević D, Lee S-K, Marusic A, Lorenzo JA. Depletion of CD4 and CD8 T Lymphocytes in mice in vivo enhances 1,25-Dihydroxyvitamin D3- stimulated osteoclast-like cell formation in vitro by a mechanism that is dependent on prostaglandin synthesis. J Immunol. 2000;165(8):4231-4238.
34. Inogès S, Rodrìguez-Cavillo M, Zabalegui N et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst. 2006;98(18):1292-1301. (Pubitemid 44530725)
35. Cairing J, Barr T, Heath AW. Adjuvanticity of anti- CD40 in vaccine development. Curr Opin Mol Ther. 2005;7(1):73-77. (Pubitemid 40287458)
36. Dullforce P, Sutton DC, Heath AW. Enhancement of T-cell independent immune responses in vivo by CD40 antibodies. Nat Med. 1998;4(1):88-91. (Pubitemid 28133085)
37. Barr TA, Heath AW. Enhanced in vivo immune responses to bacterial lipopolysaccharide by exogenous CD40 stimulation. Infect Immun. 1999; 67(7):3637-3640. (Pubitemid 29291540)
38. Bhagawati-Prasad VNS, De Leenheer E, Keefe NP, Ryan LA, Carlring J, HeathAW. CD40mAb adjuvant induces a rapid antibody response that may be beneficial in post-exposure prophylaxis. J Immune Based Ther Vaccines. 2010;8:1-3.
39. Bendandi M. Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat Rev Cancer. 2009;9(9):675-681.
40. Li J, Song W, Czerwinski DK, et al. Lymphoma immunotherapy with CpG oligonucleotides requires TLR9 either in the host or in the tumor itself. J Immunol. 2007;179(4):2493-2500.
41. Karyampudi L, Ghosh SK. Mycobacterial HSP70 as an adjuvant in the design of an idiotype vaccine against a murine lymphoma. Cell Immunol. 2008;254(1):74-80.
42. Mocikat R, Selmayr M, Thierfelder S, Lindhofer H. Trioma-based vaccination against B-cell lymphoma confers long-lasting tumor immunity. Cancer Res. 1997;57(12):2346-2349. (Pubitemid 27255886)
43. Kronenberger K, Dieckmann A, Selmayr M, et al. Impact of the lymphoma idiotype on in vivo tumor protection in a vaccination model based on targeting antigens to antigen-presenting cells. Blood. 2002;99(4):1327-1331. (Pubitemid 34547088)
44. Goldstein MJ, Varghese B, Brody JD, et al. A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors. Blood. 2011;117(1):118-127.
45. Berge G, Eliassen LT, Camilio KA, Bartnes K, Sveinbjørnsson B, Rekdal Ø. Therapeutic vaccination against a murine lymphoma by intratumoral injection of a cationic anticancer peptide. Cancer Immunol Immunother. 2010;59(8):1285-1294.
46. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105(4):1417-1423. (Pubitemid 40223656)